# Ma-Spore ALL 2020 Study

> **NCT06336395** · PHASE2 · RECRUITING · sponsor: **National University Hospital, Singapore** · enrollment: 500 (estimated)

## Conditions studied

- B Lymphoblastic Leukemia

## Interventions

- **DRUG:** Prednisolone
- **DRUG:** Dexamethasone
- **DRUG:** Vincristine
- **DRUG:** Methotrexate
- **DRUG:** L-Asparaginase
- **DRUG:** Pegylated asparaginase
- **DRUG:** Erwinase
- **DRUG:** Dasatinib
- **DRUG:** Imatinib
- **DRUG:** Cyclophosphamide
- **DRUG:** Cytarabine
- **DRUG:** Mercaptopurine
- **DRUG:** Thioguanine
- **DRUG:** Rituximab
- **DRUG:** Doxorubicin
- **DRUG:** Fludarabine

## Key facts

- **NCT ID:** NCT06336395
- **Lead sponsor:** National University Hospital, Singapore
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2020-03-04
- **Primary completion:** 2030-03
- **Final completion:** 2030-03
- **Target enrollment:** 500 (ESTIMATED)
- **Last updated:** 2024-03-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06336395

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06336395, "Ma-Spore ALL 2020 Study". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06336395. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*